Founder’s Vision

Every year, 100 million surgeries happen where the surgeon cannot see blood flow in real time. Think about that. We put rovers on Mars. We sequence the human genome over lunch. But when a surgeon is deciding where to cut, where to connect, whether tissue is alive or dying — they’re relying on technology from the 1960s. Dyes. Probes. Educated guesses.

That’s not a gap in the market. That’s a blind spot in modern medicine.

ViewFlow exists because I’ve spent two decades at the intersection of light, biology, and surfaces — and then learned what it takes to bring breakthrough science to market. At the University of Florida, I was modeling how light interacts with molecules at the femtosecond scale — a million times faster than a nanosecond. As a NASA Doctoral Fellow at Duke, I built ultrasensitive biosensors that could detect biological signals no existing tool could find. My first lesson in commercialization came from creating a cheminformatics platform and licensing it to Roche and Merck — where I learned that the hardest problem in science isn’t invention, it’s building something people will actually use. At Lockheed Martin, I spent five years developing strategy and leading proposals for federal contracts worth up to $250M — including satellite imaging and remote sensing programs built to see what the naked eye can’t. Years of advising companies like Deutsche Bank as Duke faculty sharpened that instinct further. ViewFlow is where all of it converges: the physics of light, the biology of living tissue, and the discipline to build something a surgeon will actually reach for.

So we didn’t build a better camera. We built a clinical decision-making engine. ViewFlow’s core is a vision algorithm that reads blood flow the way a weather system reads the atmosphere — pulling from many spatial and temporal dimensions simultaneously to show surgeons, in real time, what no human eye and no existing tool can see. Not a snapshot. Not a guess. A live, intuitive map of what’s happening inside the body, right now.

The clinical validation path is set. Houston Methodist has agreed to a pilot study. Duke is engaged. These are surgeons with little tolerance for anything that slows them down — and they want ViewFlow in their ORs. We’re raising capital now to get it there.

This is where surgical decision-making is going. The question was never if someone would build this. The question was who would have the right combination of physics, engineering, regulatory experience, and clinical obsession to build it right. We did.

ViewFlow. See what surgery has been waiting for.